Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab
- 25 May 2016
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 10 (12) , 1407-1416
Abstract
Background and Aims: Histological healing has emerged as a promising therapeutic goal in ulcerative colitis. This is especially important in the context of biologic therapies. The objectives of the present study were to investigate the ability of infliximab to induce histological remission in Ulcerative Colitis (UC) patients and to explore the utility of faecal calprotectin and lactoferrin in predicting histological activity. Methods: Multi-centre, single-cohort, open-label, 52-week trial including moderately to severely biologic-naïve UC patients receiving intravenous infliximab (5mg/kg). The primary outcome was the proportion of patients with histological remission (Geboes index ≤3.0) after 8 weeks of treatment, scored by two independent pathologists. Results: Twenty patients were included. The rate of histological remission increased from 5% at baseline to 15% and 35% at week 8 and week 52, respectively. At week 8, 40% of patients were in clinical remission (Mayo ≤2) and 45% achieved mucosal healing (Mayo endoscopy subscore 0-1). At week 52, 25% of patients had clinical, endoscopic and histological remission. Faecal calprotectin and lactoferrin showed the highest correlation with histological activity at week 8 (AUC 94%, p=0.017; and 96% p=0.013, respectively) and both markers revealed an excellent positive predictive value for this outcome at this time point (100%, p=0.017; and 94% p=0.013, respectively). Conclusions: Infliximab was able to induce histological remission. There was a good agreement between histology and faecal biomarkers. Faecal calprotectin and lactoferrin were good predictors of histological remission. Our data support inclusion of histology as a treatment target complementary to endoscopy in clinical trials when evaluating therapeutic response in UC. Clinicaltrials.gov Identifier: NCT01408810.Keywords
This publication has 48 references indexed in Scilit:
- Review article: the histological assessment of disease activity in ulcerative colitisAlimentary Pharmacology & Therapeutics, 2015
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current managementJournal of Crohn's and Colitis, 2012
- Mucosal healing in inflammatory bowel diseases: a systematic reviewGut, 2012
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative ColitisGastroenterology, 2011
- Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel diseaseJournal of Crohn's and Colitis, 2011
- Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel DiseaseJournal of Crohn's and Colitis, 2011
- Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs diseaseInflammatory Bowel Diseases, 2009
- A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative ColitisGastroenterology, 2007
- Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitisGut, 2006
- Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitisGastroenterology, 2001